NASDAQ:DNLI - Denali Therapeutics Stock Price, Forecast & News

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Denali Therapeutics Inc (NASDAQ:DNLI) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.08. The firm had revenue of $13.60 million for the quarter, compared to analyst estimates of $10.86 million. Denali Therapeutics had a negative return on equity of 13.37% and a negative net margin of 44.73%. View Denali Therapeutics' Earnings History.

Denali Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Denali Therapeutics.

8 brokerages have issued twelve-month target prices for Denali Therapeutics' stock. Their forecasts range from $19.00 to $37.00. On average, they expect Denali Therapeutics' stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 48.6% from the stock's current price. View Analyst Price Targets for Denali Therapeutics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics.

Headlines about DNLI stock have trended negative on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Denali Therapeutics earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Denali Therapeutics.

Denali Therapeutics saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 10,540,000 shares, an increase of 6.7% from the January 30th total of 9,880,000 shares. Based on an average daily trading volume, of 548,100 shares, the short-interest ratio is presently 19.2 days. Currently, 15.4% of the company's stock are short sold. View Denali Therapeutics' Current Options Chain.

Some companies that are related to Denali Therapeutics include Moderna (MRNA), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), argenx (ARGX), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), bluebird bio (BLUE), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO) and Crispr Therapeutics (CRSP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Kratos Defense & Security Solutions (KTOS), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Pretium Resources (PVG), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Esperion Therapeutics (ESPR) and Inseego (INSG).

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

Denali Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (7.90%), FMR LLC (4.29%), State Street Corp (1.67%), Casdin Capital LLC (1.30%), Bamco Inc. NY (0.99%) and Geode Capital Management LLC (0.90%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho and Ryan J Watts. View Institutional Ownership Trends for Denali Therapeutics.

DNLI stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, FMR LLC, Citigroup Inc., Pictet Asset Management Ltd., Bamco Inc. NY, Rafferty Asset Management LLC, SG Americas Securities LLC and AQR Capital Management LLC. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho and Ryan J Watts. View Insider Buying and Selling for Denali Therapeutics.

DNLI stock was purchased by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Marshall Wace North America L.P., Baillie Gifford & Co., Russell Investments Group Ltd., Marshall Wace LLP, Algert Global LLC, Alpine Global Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Denali Therapeutics.

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DNLI stock can currently be purchased for approximately $20.35.

Denali Therapeutics has a market capitalization of $1.95 billion and generates $129.16 million in revenue each year. The company earns $-36,240,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Denali Therapeutics employs 179 workers across the globe.View Additional Information About Denali Therapeutics.

The official website for Denali Therapeutics is http://www.denalitherapeutics.com/.

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.